Therefore, both blocking CSNK2A1 and SIRT6 or the direct suppression of the DNA damage repair pathway might be promising therapeutic strategies to overcome cancer resistance to conventional genotoxic anti-cancer therapeutics. This evidence concerns the gene CSNK2A1 and cancer.